4-tert-butyl-2-fluorobenzoic acid | 932400-17-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-tert-butyl-2-fluorobenzoic acid
• 英文别名: 4-(Tert-butyl)-2-fluorobenzoic acid
• CAS: 932400-17-4
• 化学式: C₁₁H₁₃FO₂
• 分子量: 196.221
• InChiKey: UGLNBDINYJXPIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-tert-butyl-2-fluorobenzoic acid 在 草酰氯 、 氨 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 4-tert-butyl-2-fluorobenzamide
  参考文献：
  名称：

  2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER

  摘要：

  公开号：

  EP1955697B1
• 作为产物：
  描述：

  methyl 4-tert-butyl-2-fluorobenzoate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以100%的产率得到4-tert-butyl-2-fluorobenzoic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE
  [FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON

  摘要：

  公开号：

  WO2016196776A3

文献信息

• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE
  申请人：VERTEX PHARMA

  公开号：WO2021030556A1

  公开（公告）日：2021-02-18

  This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

  这份披露提供了囊性纤维化跨膜传导调节蛋白（CFTR）的调节剂，包含至少一种这样的调节剂的药物组合物，使用这种调节剂和药物组合物治疗囊性纤维化的方法，以及制造这种调节剂的过程。
• 2-AMINOBENZAMIDE DERIVATIVE
  申请人：Kuramochi Takahiro

  公开号：US20090233900A1

  公开（公告）日：2009-09-17

  To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.

  本发明提供了一种基于对辣椒素受体VR1激活的抑制作用的新型优良药剂，用于治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等疾病。本发明通过确认一种苯甲酰胺衍生物，其特征在于其苯环上的单环在酰胺基氮原子上被紧缩，其低烷基氨基或邻位于酰胺基的环基取代的氨基具有对VR1激活的强抑制作用和优良的药理作用，从而发现它可以成为治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等VR1相关疾病的优良药剂。
• 2-aminobenzamide derivatives
  申请人：Astellas Pharma Inc.

  公开号：US08106190B2

  公开（公告）日：2012-01-31

  To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.

  为了提供一种新颖且优秀的药剂，用于治疗或预防嗜痛性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等，基于对辣椒素受体VR1激活的抑制作用。本发明通过确认一种苯甲酰胺衍生物，其特征在于其苯环上的单环在酰胺基团的氮原子上凝聚，并具有一个邻位取代环基的较低烷基氨基或氨基团，具有对VR1激活的强抑制作用和基于此的优异药理学作用，并发现它可以成为治疗或预防嗜痛性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等VR1相关疾病的优秀药剂。
• RORgammaT INHIBITORS
  申请人：Karstens Willem Frederik Johan

  公开号：US20140038942A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.

  本发明涉及公式（I）或其药学上可接受的盐或溶剂的化合物。这样的化合物可用于治疗RORgammaT介导的疾病或病况。
• SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR
  申请人：LUPIN LIMITED

  公开号：US20160250219A1

  公开（公告）日：2016-09-01

  Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I).

  公式（I）的化合物及其制备方法，可用于治疗、管理和/或减轻与钙感受（CaSR）受体调节相关的疾病、紊乱、综合征或病况。治疗、管理和/或减轻公式（I）的钙感受（CaSR）受体调节相关疾病、紊乱、综合征或病况的方法。